Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

KPTI Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Karyopharm Therapeutics Inc.NASDAQ: KPTI

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow grows to $49.8M

Q1 FY2026 financing cash flow was $49.8M, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $79.85M. Over 3 fiscal years it compounded at -46.3% a year.

Context

  • Financing cash flow amounted to 20.6% of revenue in FY2025, down 8.1 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near $49.8M or moves back toward the trailing-twelve-month quarterly average of $19.96M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$49.8M+67.7% QoQ
Last fiscal yearDec 2025
$30.05M-27.8% YoY
LTMMar 2026
$79.85M+91.7% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-27.8%——
3-year CAGR-46.3%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
30.05M USD
Year-over-year change
-27.8%
4-year CAGR
-20.1%

Financing Cash Flow vs competitors

How KPTI compares with its peers on the latest reported figures

  • KPTI's LTM Mar 2026 financing cash flow of $79.85M is the 2nd largest of the 4 companies compared; the peer median is $22.34M.
  • Its year-over-year change of +91.7% is the 3rd highest of 4, against a peer median of +768.9%.
  • Financing cash flow amounts to 52.8% of revenue for KPTI, versus a peer median of 2647.3%.
KPTI Competitors Peer median
Financing Cash Flow for KPTI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$238.63M +1075.9%+26.7%2647.3%
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$79.85M +91.7%-46.3%52.8%
INMBINmune Bio, Inc.LTM Mar 2026$22.34M -14.0%+235.8%—
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$9.76M +768.9%+174.4%—
Peer median (excluding KPTI) $22.34M+768.9%+174.4%2647.3%

Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Depreciation & Amortization789K621K530K340K(114K)
Deferred Income Tax1.45M0000
Stock-Based Compensation29.78M35.4M21.71M18.43M14.05M
Change in Working Capital(23.19M)(19.99M)31.42M(302K)28.27M
Accounts Receivables(9.62M)(5.08M)20.12M(3.8M)4.59M
Inventory(1.46M)(118K)1.18M(1.7M)701K
Accounts Payables(2.85M)1.17M350K1.98M(1.1M)
Other Working Capital(9.26M)(15.96M)9.76M3.21M24.09M
Other Non-Cash Items8.14M(294K)(3.28M)(69.53M)78.46M
Operating Cash Flow(107.12M)(149.55M)(92.72M)(127.49M)(75.37M)
Capital Expenditures(5.71M)(118K)0(142K)0
Acquisitions (Net)5.5M104.26M000
Purchases of Investments(45.23M)(226.02M)(159.15M)(58.82M)0
Sales of Investments192.78M121.88M167.09M154.44M43.38M
Other Investing Activities(5.5M)(104.26M)000
Investing Cash Flow141.84M(104.26M)7.94M95.47M43.38M
Debt Repayment60M0083.3M20.54M
Common Stock Issued9.9M189.76M1.12M1.45M9.51M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.75M3.98M0(43.11M)0
Financing Cash Flow73.65M193.74M1.12M41.65M30.05M
Effect of Forex Changes(48K)(488K)(34K)(11K)20K
Net Change in Cash108.32M(60.56M)(83.69M)9.62M(1.92M)
Free Cash Flow(112.83M)(149.67M)(92.72M)(127.63M)(75.37M)

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Intrinsic Alpha fair value

Locked

Current Price

$7.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.